Regeneron Pharmaceuticals Inc (NASDAQ: REGN) has reported earnings for its second fiscal quarter (ending June 30) of $13.25 versus $9.05 for the same period a year ago. E.P.S. were $40.31 for the latest four quarters through June 30 versus $40.19 for the same period a year ago.
Recent Price Action
On 8/1/24, Regeneron Pharmaceuticals Inc (NASDAQ: REGN) stock increased 1.3%, closing at $1093.14. Moreover, trading volume in this advance was exceptionally high at 201% of normal. Relative to the market the stock has been strong over the last nine months and has risen 3.0% during the last week.
Current PriceTarget Research Rating
REGN’s future returns on capital are forecasted to be above the cost of capital. Accordingly, the company is expected to continue to be an important Value Builder.
Regeneron Pharmaceuticals has a current Value Trend Rating of B (Positive). This rating combines consistent signals from two proprietary PTR measures of a stock’s attractiveness. Regeneron Pharmaceuticals has a slightly positive Appreciation Score of 62 and a good Power Rating of 75, resulting in the Positive Value Trend Rating.
Rating Review
In light of this new information and positive market action we are reviewing our current Overall Rating of B. This review will be completed in the next several days.
Be the first to comment